Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients

1Cancer in Slovenia 2015 Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of republic of Slovenia; 2018. Cancer in Slovenia 2015 Ljubljana Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of republic of Slovenia 2018Search in Google Scholar

2Schmoll1 HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516. doi: 10.1093/annonc/mds236 Schmoll1 HJ Van Cutsem E Stein A Valentini V Glimelius B Haustermans K ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 2012 23 2479516 10.1093/annonc/mds236Open DOISearch in Google Scholar

3Van Cutsem1 E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 1386-422. doi: 10.1093/annonc/mdw235 Van Cutsem1 E Cervantes A Adam R Sobrero A Van Krieken JH Aderka D ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Ann Oncol 2016 1386422 10.1093/annonc/mdw235Open DOISearch in Google Scholar

4National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer. V.2.2018. [cited 2018 Jun 15]. Available at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdf National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: colon cancer. V.2.2018 [cited 2018 Jun 15]. Available at http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdfSearch in Google Scholar

5National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: rectal cancer. V.2.2018 [cited 2018 Aug 3]. Available at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdf National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: rectal cancer. V.2.2018 [cited 2018 Aug 3]. Available at http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdfSearch in Google Scholar

6Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. A systemic review and meta-analysis. JAMA 2011; 305: 233542. doi: 10.1001/jama.2011.749 Biagi JJ Raphael MJ Mackillop WJ Kong W King WD Booth CM Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. A systemic review and meta-analysis JAMA 2011 305 233542 10.1001/jama.2011.749Open DOISearch in Google Scholar

7Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8. doi: 10.2478/v10019-009-0004-1 Ocvirk J Advances in the treatment of metastatic colorectal carcinoma Radiol Oncol 2009 43 18 10.2478/v10019-009-0004-1Open DOISearch in Google Scholar

8Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl Med 2005; 352: 476-87. doi: 10.1053/j.gastro.2008.02.098 Meyerhardt JA Mayer RJ Systemic therapy for colorectal cancer N Engl Med 2005 352 47687 10.1053/j.gastro.2008.02.098Open DOISearch in Google Scholar

9Esin E, Yalcin S. Maintenance strategy in metastatic colorectal cancer: a systematic review. Cancer Treat Rev 2016; 42: 82-90. doi: 10.1016/j. ctrv.2015.10.012 Esin E Yalcin S Maintenance strategy in metastatic colorectal cancer: a systematic review Cancer Treat Rev 2016 42 8290 10.1016/j ctrv.2015.10.012Open DOISearch in Google Scholar

10Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment. Ann Oncol 2010; 21: v93- 7. doi: 10.1093/annonc/mdq222 Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment Ann Oncol 2010 21 v937 10.1093/annonc/mdq222Open DOISearch in Google Scholar

11Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60. doi: 10.1056/NEJMra0804588 Markowitz SD Bertagnolli MM Molecular basis of colorectal cancer N Engl J Med 2009 361 244960 10.1056/NEJMra0804588Open DOISearch in Google Scholar

12De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812- 20. doi: 10.1001/jama.2010.1535 De Roock W Jonker DJ Di Nicolantonio F Sartore-Bianchi A Tu D Siena S Lamba S Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 2010 304 181220 10.1001/jama.2010.1535Open DOISearch in Google Scholar

13De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62. doi: 10.1016/S1470-2045(10)70130-3 De Roock W Claes B Bernasconi D De Schutter J Biesmans B Fountzilas G Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 2010 11 75362 10.1016/S1470-2045(10)70130-3Open DOISearch in Google Scholar

14Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99. doi: 10.3978/j.issn.2078-6891.2015.077 Tol J Nagtegaal ID Punt CJA BRAF mutation in metastatic colorectal cancer N Engl J Med 2009 361 9899 10.3978/j.issn.2078-6891.2015.077Open DOISearch in Google Scholar

15Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite- stable colon cancer. Caner Res 2005; 65: 6063-9. doi: 10.1158/0008-5472.CAN-05-0404 Samowitz WS Sweeney C Herrick J Albertsen H Levin TR Murtaugh MA Poor survival associated with the BRAF V600E mutation in microsatellite- stable colon cancer Caner Res 2005 65 60639 10.1158/0008-5472.CAN-05-0404Open DOISearch in Google Scholar

16Ličar A, Cerkovnik P, Novaković S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 2011; 28: 1048-53. doi: 10.1007/s12032-010-9631-z Ličar A Cerkovnik PNovaković S Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer Med Oncol 2011 28 104853 10.1007/s12032-010-9631-zOpen DOISearch in Google Scholar

17Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-402. doi: 10.1093/annonc/mdq258 Fariña-Sarasqueta A van Lijnschoten G Moerland E Creemers GJ Lemmens VE Rutten HJ The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients Ann Oncol 2010 21 2396402 10.1093/annonc/mdq258Open DOISearch in Google Scholar

18Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi: 10.1016/j.ejca.2008.10.026 Eisenhauer EA Therasse P Bogaerts J Schwartz LH Sargent D Ford R New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) Eur J Cancer 2009 45 22847 10.1016/j.ejca.2008.10.026Open DOISearch in Google Scholar

19Marzouk O, Schofield J. Review of histopathological and molecular prognostic features in colorectal cancer. Cancers 2011; 3: 276-81. doi: 10.3390/cancers3022767 Marzouk O Schofield J Review of histopathological and molecular prognostic features in colorectal cancer Cancers 2011 3 27681 10.3390/cancers3022767Open DOISearch in Google Scholar

20Ličar A, Cerkovnik P, Ocvirk J, Novaković S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol 2010; 36: 1137-44. doi: 10.3892/ijo_00000596. Ličar A Cerkovnik P Ocvirk J Novaković S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment Int J Oncol 2010 36 113744 10.3892/ijo_00000596Open DOISearch in Google Scholar

21Artale S, Sartore- Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217- 9. doi: 10.1200/JCO.2008.18.7266 Artale S Sartore- Bianchi A Veronese SM Gambi V Sarnataro CS Gambacorta M Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer J Clin Oncol 2008 26 42179 10.1200/JCO.2008.18.7266Open DOISearch in Google Scholar

22Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 146675. doi: 10.1016/j.ejca.2012.02.057 Bokemeyer C Van Cutsem E Rougier P Ciardiello F Heeger S Schlichting M Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 2012 48 146675 10.1016/j.ejca.2012.02.057Open DOISearch in Google Scholar

23Artale S, Sartore- Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-9. doi: 10.1200/JCO.2008.18.7286 Artale S Sartore- Bianchi A Veronese SM Gambi V Sarnataro CS Gambacorta M Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer J Clin Oncol 2008 26 42179 10.1200/JCO.2008.18.7286Open DOISearch in Google Scholar

24Rebersek M, Boc M, Škerl P, Benedik J, Hlebanja Z, Volk N, et al. Efficacy of first- line systemic treatment in correlation with BRAF V600E and different KRAS mutations colorectal cancer - a single institution retrospective analysis. Radiol Oncol 2011; 45: 285-91. doi: 10.2478/v10019-011-0039-y Rebersek M Boc M Škerl P Benedik J Hlebanja Z Volk N Efficacy of first- line systemic treatment in correlation with BRAF V600E and different KRAS mutations colorectal cancer - a single institution retrospective analysis Radiol Oncol 2011 45 28591 10.2478/v10019-011-0039-yOpen DOISearch in Google Scholar

25Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, et al. The role of KRAS, BRAF, NRAS and PIK3CA mutations as a markers of resistance of cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol 2009; 27: 9020. doi: 10.1158/1078-0432.CCR-08-2961 Lambrechts D De Roock W Prenen H De Schutter J Jacobs B Biesmans B The role of KRAS, BRAF, NRAS and PIK3CA mutations as a markers of resistance of cetuximab in chemorefractory metastatic colorectal cancer J Clin Oncol 2009 27 9020 10.1158/1078-0432.CCR-08-2961Open DOISearch in Google Scholar

26Tejpar S, De Roock W. PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated With EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium[abstract]. Eur J Cancer Suppl 2009; 7: 322. No. 6005 Tejpar S De Roock W. PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated With EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium[abstract] Eur J Cancer Suppl 2009 7 322 6005Search in Google Scholar

27Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-21. doi: 10.18632/oncotarget.13697 Loupakis F Ruzzo A Cremolini C Vincenzi B Salvatore L Santini D KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 2009 101 71521 10.18632/oncotarget.13697Open DOISearch in Google Scholar

28Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-7. doi: 10.1200/JCO.2012.42.2592 Tejpar S Celik I Schlichting M Sartorius U Bokemeyer C Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 2012 30 35707 10.1200/JCO.2012.42.2592Open DOISearch in Google Scholar

29Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-65. doi: 10.1200/JCO.2012.45.1492. Epub 2012 Nov 26. Peeters M Douillard JY Van Cutsem E Siena S Zhang K Williams R Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab J Clin Oncol 2013 31 75965 10.1200/JCO.2012.45.1492 Epub 2012 Nov 26Open DOISearch in Google Scholar

30Roth AD, Tejpar S, Dolorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010: 28: 466-74. doi: 10.1200/JCO.2009.23.3452. Roth AD Tejpar S Dolorenzi M Yan P Fiocca R Klingbiel D Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 2010 28 46674 10.1200/JCO.2009.23.3452Open DOISearch in Google Scholar

31Fujiyoshi K, Yamamoto G, Takahashi A, Arai Y, Yamada M, Kakuta M, et al. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep 2017; 37: 785-92. doi: 10.3892/or.2016.5323. Fujiyoshi K Yamamoto G Takahashi A Arai Y Yamada M Kakuta M High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases Oncol Rep 2017 37 78592 10.3892/or.2016.5323Open DOISearch in Google Scholar

32Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94: 76-81. doi: 10.1016/j. radonc.2009.10.001 Gaedcke J Grade M Jung K Schirmer M Jo P Obermeyer C KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy Radiother Oncol 2010 94 7681 10.1016/j radonc.2009.10.001Open DOISearch in Google Scholar

33Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2015; 96: 156-66. doi: 10.1016/j.critrevonc.2015.05.016 Pietrantonio F Cremolini C Petrelli F Di Bartolomeo M Loupakis F Maggi C First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis Crit Rev Oncol Hematol 2015 96 15666 10.1016/j.critrevonc.2015.05.016Open DOISearch in Google Scholar

34Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26: 13-21. doi: 10.1093/annonc/mdu378 Sorich MJ Wiese MD Rowland A Kichenadasse G McKinnon RA Karapetis CS Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials Ann Oncol 2015 26 1321 10.1093/annonc/mdu378Open DOISearch in Google Scholar

35Scartozzi M, Galizia E, Chiorrini S, Giampieri G, Berardi R, Pieratoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer treated with first- line bevacizumab. Clin Oncol 2009; 20: 227-30. doi: 10.1093/annonc/mdn637 Scartozzi M Galizia E Chiorrini S Giampieri G Berardi R Pieratoni C Arterial hypertension correlates with clinical outcome in colorectal cancer treated with first- line bevacizumab Clin Oncol 2009 20 22730 10.1093/annonc/mdn637Open DOISearch in Google Scholar

36Mir O, Ropert S, Alexandre J, Goldwasser F. Hypertension as a surrogate marker for the activity of anti- VEGF agents. Ann Oncol 2009; 20: 967-70. doi: 10.1093/annonc/mdp206 Mir O Ropert S Alexandre J Goldwasser F Hypertension as a surrogate marker for the activity of anti- VEGF agents Ann Oncol 2009 20 96770 10.1093/annonc/mdp206Open DOISearch in Google Scholar

37Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, et al. Effect of renal impairment on the pharmacokinetics and tolarebility of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49: 225-34. doi: 10.1007/s00280-001-4808-0 Poole C Gardiner J Twelves C Johnston P Harper P Cassidy J Effect of renal impairment on the pharmacokinetics and tolarebility of capecitabine (Xeloda) in cancer patients Cancer Chemother Pharmacol 2002 49 22534 10.1007/s00280-001-4808-0Open DOISearch in Google Scholar

38Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-75. doi: 10.1200/JCO.2001.19.21.4097 Cassidy J Twelves C Van Cutsem E Hoff P Bajetta E Boyer M First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin Ann Oncol 2002 13 56675 10.1200/JCO.2001.19.21.4097Open DOISearch in Google Scholar

39Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1* 28 genotype and irinotecan- induced neutropenia: dose matters. J Nati Cancer Inst 2007; 99: 1290-421. doi: 10.1200/JCO.2009.21.7943 Hoskins JM Goldberg RM Qu P Ibrahim JG McLeod HL UGT1A1* 28 genotype and irinotecan- induced neutropenia: dose matters J Nati Cancer Inst 2007 99 1290421 10.1200/JCO.2009.21.7943Open DOISearch in Google Scholar

40Hoskins JM, McLeod HL. UGT1A and irinotecan toxicity: keeping it in the family. J Clin Oncol 2009; 27: 2419-21. doi: 10.2217/pgs.10.95 Hoskins JM McLeod HL UGT1A and irinotecan toxicity: keeping it in the family J Clin Oncol 2009 27 241921 10.2217/pgs.10.95Open DOISearch in Google Scholar

41Pereg D, Lishner M. Bevacizumab treatment for cancer treatment with cardiovascular disease: a double edged sword? Eur Heart J 2008; 29: 2325-26. doi: 10.1093/eurheartj/ehn384. Pereg D Lishner M Bevacizumab treatment for cancer treatment with cardiovascular disease: a double edged sword? Eur Heart J 2008 29 232526 10.1093/eurheartj/ehn384Open DOISearch in Google Scholar

42Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. J Nati Cancer Inst 2007; 1232-9. 0.1093/jnci/djm086 Scappaticci FA Skillings JR Holden SN Gerber HP Miller K Kabbinavar F Arterial thromboembolic events in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab J Nati Cancer Inst 2007 12329 0.1093/jnci/djm086Open DOISearch in Google Scholar

43Lee CS, Ryan EJ, Glen A Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol 2014; 20: 3751-61. doi: 10.3748/wjg.v20.i14.3751 Lee CS Ryan EJ Glen A Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation World J Gastroenterol 2014 20 375161 10.3748/wjg.v20.i14.3751Open DOISearch in Google Scholar

44Ocvirk J, Rebersek M. Management of cutaneous side effect of cetuximab therapy with K1 creme. Radiol Oncol 2008; 42: 215-24. doi: 10.2478/v10019-008-0022-4 Ocvirk J Rebersek M Management of cutaneous side effect of cetuximab therapy with K1 creme Radiol Oncol 2008 42 21524 10.2478/v10019-008-0022-4Open DOISearch in Google Scholar

45Ocvirk J, Cencelj S. Management of cutaneous side-effect of cetuximab therapy in patients with metastatic colorectal cancer. JEADV 2010; 24: 4539. doi: 10.1111/j.1468-3083.2009.03446.x Ocvirk J Cencelj S Management of cutaneous side-effect of cetuximab therapy in patients with metastatic colorectal cancer JEADV 2010 24 4539 10.1111/j.1468-3083.2009.03446.xOpen DOISearch in Google Scholar

46Ocvirk J, Rebersek M, Boc M, Mesti T, Ebert Moltara M. Prophylactic use of K1 crem for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2016; 28(15 Suppl): V124. doi: 10.1200/jco.2010.28.15_suppl.e14011. Ocvirk J Rebersek M Boc M Mesti T Ebert Moltara M. Prophylactic use of K1 crem for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC) J Clin Oncol 2016 2815 Suppl V124 10.1200/jco.2010.28.15_suppl.e14011Open DOISearch in Google Scholar

47Siena S, Glynne-Jones R, Adenis A, Thaler J, Preusser P, Aguilar EA, et al. Reduced incidence of infusion- related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamin premedication. Cancer 2010, 116: 1827-37. doi: 10.1002/cncr.24945 Siena S Glynne-Jones R Adenis A Thaler J Preusser P Aguilar EA Reduced incidence of infusion- related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamin premedication Cancer 2010 116 182737 10.1002/cncr.24945Open DOISearch in Google Scholar

48Venderbosch, ID Nagtegaal, TS Maughan, CG Smith , JP Cheadle, D Fisher, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014 20: 5322-30. doi: 10.1158/1078-0432. CCR-14-0332 Venderbosch ID Nagtegaal Maughan TS Smith CG Cheadle JP Fisher D Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies Clin Cancer Res 2014 20 532230 10.1158/1078-0432 CCR-14-0332Open DOISearch in Google Scholar

49Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-20. doi: 10.1056/NEJMoa1500596 Le DT Uram JN Wang H Bartlett BR Kemberling H Eyring AD PD-1 blockade in tumors with mismatch-repair deficiency N Engl J Med 2015 372 250920 10.1056/NEJMoa1500596Open DOISearch in Google Scholar

50Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014; 53: 852-64. doi: 10.3109/0284186X.201 4.895036 Therkildsen C Bergmann TK Henrichsen-Schnack T Ladelund S Nilbert M The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis Acta Oncol 2014 53 85264 10.3109/0284186X.201 4.895036Open DOISearch in Google Scholar